Table 1. Cytotoxicity of T cells expressing anti-CD38-CAR against HTLV-1-transformed cells and ATL cells.
Cells | Percentage of CD38+ cells (%) | Overall cytotoxicity of anti-CD38-CAR T cells by LDH assay (%) | Percentage of CD38+ cells with ATRA (%) | Specific cytotoxicity of anti-CD38-CAR T cells against CD38+ cells with ATRA by FCM (%) | Overall cytotoxicity of anti-CD38-CAR T cells with ATRA by FCM (%) |
---|---|---|---|---|---|
MT-2 | 97.06±1.00 | 75.36±0.11 | 97.19±1.47 | 99.90±0.09 | 92.30±1.48 |
MT-4 | 2.91±0.31 | 4.97±1.18 | 97.81±0.36 | 98.61±0.12 | 97.92±0.33 |
S1T | 0.01±0.01 | 0.73±0.34 | 81.34±1.35 | 96.98±0.09 | 81.08±1.12 |
Hut102 | 1.18±0.13 | 2.74±3.36 | 86.11±3.94 | 99.51±0.02 | 86.47±2.74 |
Su9T | 0.05±0.04 | 1.61±1.49 | 0.04±0.03 | ND | ND |
ED | 0.01±0.01 | 2.60±0.61 | 0.05±0.04 | ND | ND |
Patient 1 | 29.21±0.88 | ND | 58.81±1.24 | 99.84±0.22 | 58.70±1.11 |
Patient 2 | 5.24±0.89 | ND | 79.58±1.19 | 92.42±2.02 | 74.40±1.94 |
Patient 3 | 0.01±0.02 | ND | 0.04±0.01 | ND | ND |
Cells | Expression of CD38 (%) | Expression of CD38 with ATRA (%) | Expression of CD38 with IFN-α (%) | Expression of CD38 with ATRA and IFN-α (%) | Overall cytotoxicity of anti-CD38-CAR T cells with ATRA/IFN-α by FCM (%) |
---|---|---|---|---|---|
Patient 4 | 34.94±1.39 | 78.70±2.00 | 66.48±0.81 | 95.45±0.91 | 99.68±0.18 |
Patient 5 | 50.36±1.30 | 70.36±1.21 | 74.03±0.44 | 93.41±1.04 | 95.98±0.17 |
Patient 6 | 82.01±1.40 | 91.15±0.92 | 97.64±0.42 | 97.55±0.71 | 99.92±0.02 |
Abbreviations: ATL, adult T-cell leukemia; ATRA, all-trans retinoic acid; CAR, chimeric antigen receptor; FCM, flow cytometry; HTLV-1, human T-cell lymphotropic virus type-1; IFN-α, interferon-α LDH, lactate dehydrogenase; ND, not determined.
Results are the mean±s.d. for three experiments.
Specific cytotoxicity was evaluated by flow cytometry, following co-incubation of T cells bearing anti-CD38-CAR (E) with ATL cells (T) at an E:T ratio of 1:2 for 3 days.